NX-2127

Target: This ligand targets Bruton tyrosine kinase (BTK) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for Bruton tyrosine kinase (BTK). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings Bruton tyrosine kinase (BTK) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Driven Target Degradation: NX-2127 can be used as a PROTAC ligand to recruit an E3 ubiquitin ligase to a chosen target protein, enabling ubiquitination and proteasome-dependent degradation. This application supports systematic evaluation of degradation potency, kinetics, and dose-response behavior in cell-based assays using target engagement and protein turnover readouts.

• E3 Ligase Recruitment Optimization: NX-2127-derived PROTAC constructs can be engineered to tune E3 ligase proximity and ubiquitination efficiency. Researchers can vary linker length, attachment sites, and stereochemistry to optimize ternary complex formation, thereby improving degradation selectivity and minimizing residual target stabilization compared with non-degrading controls.

• Mechanism-of-Action Validation: NX-2127-enabled PROTACs are suitable for mechanistic studies using proteasome and neddylation pathway perturbation. By testing degradation sensitivity to inhibitors and assessing ubiquitin conjugates, researchers can confirm whether NX-2127-based chimeras drive canonical ubiquitin–proteasome degradation rather than alternative clearance routes.

• Proteome-Wide Specificity Profiling: NX-2127 can support PROTAC discovery workflows that assess off-target degradation risk. Combining NX-2127-based PROTAC treatment with proteomics enables identification of unintended substrates, mapping degradation signatures, and refining chimera design to enhance target specificity while preserving desired pathway modulation.

NX-2127 is a BTK kinase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of NX-2127 is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.